DelveInsight’s, “Vasculitis Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Vasculitis pipeline landscape. It covers the Vasculitis pipeline drug profiles, including Vasculitis clinical trials and nonclinical stage products. It also covers the Vasculitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Vasculitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Vasculitis NDA approvals (if any), and product development activities comprising the technology, Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Vasculitis Pipeline Report
To explore more information on the latest breakthroughs in the Vasculitis Pipeline treatment landscape of the report, click here @ Vasculitis Pipeline Outlook
Vasculitis Overview
Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can result in organ and tissue damage. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis can have general symptoms like fever, loss of appetite, weight loss, and fatigue. Treatment depends on what’s causing your vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generaaly preferred to fight inflammation.
Latest Developmental Activities in the Vasculitis Treatment Landscape
For further information, refer to the detailed Vasculitis Unmet Needs, Vasculitis Market Drivers, and Vasculitis Market Barriers, click here for Vasculitis Ongoing Clinical Trial Analysis
Vasculitis Emerging Drugs Profile
Upadacitinib: AbbVie
Upadacitinib(RINVOQ) is discovered and developed by AbbVie scientists.RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs. JAK-2, JAK-3 and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.Phase III trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.
Belimumab: GlaxoSmithKline
Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response. It is being studied in phase III stage of development for the treatment of Anti-neutrophil cytoplasmic antibody-associated Vasculitis.
Secukinumab :Novartis
Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin 17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis. There also are experimental and preclinical data that point towards a role for IL-17A in the pathogenesis of giant cell arteritis, and therefore IL-17A inhibition by blocking vascular inflammation is potentially a new therapeutic target. Secukinumab showed promise as a steroid-sparing agent in giant cell arteritis. Currently the drug is in Phase III stage of evaluation for the treatment Giant Cell Arteritis (GCA). Giant cell arteritis (GCA) is the most common form of vasculitis that occurs in adults.
Vasculitis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Vasculitis. The companies which have their Vasculitis drug candidates in the most advanced stage, i.e. phase III include AbbVie.
Request a sample and discover the recent advances in Vasculitis Ongoing Clinical Trial Analysis and Medications, click here @ Vasculitis Treatment Landscape
Scope of the Vasculitis Pipeline Report
Dive deep into rich insights for drugs for Vasculitis Market Drivers and Vasculitis Market Barriers, click here @ Vasculitis Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Vasculitis Mergers and acquisitions, Vasculitis Licensing Activities @ Vasculitis Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NV 89107Country: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services